Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme.
Bevacizumab
CDKN1A c.93C > A
Glioblastoma
PCR–RFLP
Polymorphism
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
received:
30
05
2023
accepted:
13
09
2023
medline:
22
9
2023
pubmed:
21
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
Glioblastoma (GBM), a prevalent and malignant brain tumor, poses a challenge in surgical resection due to its invasive nature within the brain parenchyma. CDKN1A (p21, Waf-1), a cyclin-dependent kinase inhibitor, plays a pivotal role in regulating cell growth arrest, terminal differentiation, and apoptosis. The existence of natural variants of CDKN1A has been associated with specific cancer types. In this retrospective study, our objective was to identify polymorphic variants of CDKN1A, specifically c.93C > A (codon 31 Ser31Arg), and investigate its potential impact within the scope of bevacizumab therapy for glioblastoma multiforme. This study involved a cohort of 139 unrelated adult Chinese GBM patients in Taiwan. Genomic DNA extracted from tumor samples was utilized for genotyping using the polymerase chain reaction (PCR) restriction fragment length polymorphism method (PCR-RFLP analysis). Through unconditional logistic regression analysis, odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated. Our findings unveiled that among these GBM patients, the distribution of codon 31 polymorphisms was as follows: 23.02% were Serine homozygotes (Ser/Ser), 27.34% were Arginine homozygotes (Arg/Arg), and 49.64% were Serine/Arginine heterozygotes (Ser/Arg). While CDKN1A c.93C > A polymorphisms did not exhibit a direct association with overall survival in GBM patients, noteworthy survival benefits emerged among individuals with Arg/Arg and Arg/Ser genotypes who received combined concurrent chemoradiotherapy (CCRT) and bevacizumab treatment compared to those who underwent CCRT alone. Our findings indicate a significant involvement of the CDKN1A c.93C > A polymorphism in the development and onset of GBM, offering potential implications for the early prognostication of bevacizumab therapy outcomes.
Identifiants
pubmed: 37730565
doi: 10.1186/s12885-023-11400-5
pii: 10.1186/s12885-023-11400-5
pmc: PMC10510274
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Arginine
94ZLA3W45F
Codon
0
CDKN1A protein, human
0
Cyclin-Dependent Kinase Inhibitor p21
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
886Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
De Waele J, Verhezen T, van der Heijden S, Berneman ZN, Peeters M, Lardon F, Wouters A, Smits E. A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. J Exp Clin Cancer Res. 2021;40(1):213.
pubmed: 34172082
pmcid: 8229304
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
pubmed: 15758009
Chien LN, Gittleman H, Ostrom QT, Hung KS, Sloan AE, Hsieh YC, Kruchko C, Rogers LR, Wang YF, Chiou HY, et al. Comparative brain and central nervous system tumor incidence and survival between the United States and Taiwan based on population-based registry. Front Public Health. 2016;4:151.
pubmed: 27493936
pmcid: 4954825
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.
pubmed: 15136787
Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131–8.
pubmed: 19897538
Zhang T, Xin Q, Kang JM. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(21):6480–91.
pubmed: 34787852
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
pubmed: 19269895
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl 5):v1-49.
pubmed: 23095881
pmcid: 3480240
Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085–91.
pubmed: 24101040
pmcid: 3816958
Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015;33(10):1197–213.
pubmed: 25713439
pmcid: 4517055
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817–25.
pubmed: 8242752
Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle. 2004;3(2):134–7.
pubmed: 14712074
Viatour P, Sage J. Newly identified aspects of tumor suppression by RB. Dis Model Mech. 2011;4(5):581–5.
pubmed: 21878458
pmcid: 3180221
Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002;179(1):1–14.
pubmed: 11880176
Pruneri G, Pignataro L, Carboni N, Buffa R, Di Finizio D, Cesana BM, Neri A. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol. 1999;17(10):3150–9.
pubmed: 10506612
Liu J, Hu Y, Hu W, Xie X, Ela Bella A, Fu J, Rao D. Expression and prognostic relevance of p21WAF1 in stage III esophageal squamous cell carcinoma. Dis Esophagus. 2012;25(1):67–71.
pubmed: 21689205
Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, Wei Q. Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2005;26(9):1596–602.
pubmed: 15878916
Sun Y, Hildesheim A, Li H, Li Y, Chen JY, Cheng YJ, Hayes RB, Rothman N, Bi WF, Cao Y, et al. No point mutation but a codon 31ser–>arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev. 1995;4(3):261–7.
pubmed: 7606201
Wu MT, Wu DC, Hsu HK, Kao EL, Yang CH, Lee JM. Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett. 2003;201(2):175–80.
pubmed: 14607331
Mousses S, Ozcelik H, Lee PD, Malkin D, Bull SB, Andrulis IL. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum Mol Genet. 1995;4(6):1089–92.
pubmed: 7655464
Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2010;2(5):a001032.
pubmed: 20452958
pmcid: 2857176
Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(1):127–30.
pubmed: 11815410
Roh J, Kim M, Kim J, Park N, Song Y, Kang S, Lee H. Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett. 2001;165(1):59–62.
pubmed: 11248419
Shen CC, Cheng WY, Lee CH, Dai XJ, Chiao MT, Liang YJ, Hsieh WY, Mao TF, Lin GS, Chen SR, et al. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer. 2020;20(1):709.
pubmed: 32727419
pmcid: 7391574
Yang W, Qi Q, Zhang H, Xu W, Chen Z, Wang L, Wang Y, Dong X, Jiao H, Huo Z. p21 Waf1/Cip1 polymorphisms and risk of esophageal cancer. Ann Surg Oncol. 2010;17(5):1453–8.
pubmed: 20112071
Wu MT, Chen MC, Wu DC. Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett. 2004;205(1):61–8.
pubmed: 15036662
Xi YG, Ding KY, Su XL, Chen DF, You WC, Shen Y, Ke Y. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25(11):2201–6.
pubmed: 15240512
Liu B, Zhang Y, Jin M, Ni Q, Liang X, Ma X, Yao K, Li Q, Chen K. Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol Carcinog. 2010;49(1):75–84.
pubmed: 19795398
Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, Loeffler JS, Selker RG, Shapiro WR, Chanock SJ, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16(8):1655–61.
pubmed: 17684142
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, et al. The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer. Clin Cancer Res. 2006;12(20 Pt 1):6000–4.
pubmed: 17062672
Souto-Garcia A, Fernandez-Somoano A, Pascual T, Alvarez-Avellon SM, Tardon A. Association of p21 Ser31Arg and p53 Arg72Pro polymorphisms with lung cancer risk in CAPUA study. Lung Cancer (Auckl). 2012;3:69–78.
pubmed: 28210126
Urup T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, Bennedbaek M, Toft A, Olsen LR, Jonson L, Issazadeh-Navikas S, Broholm H, et al. Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer. 2017;17(1):278.
pubmed: 28420326
pmcid: 5395849
Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, et al. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res. 2015;21(8):1851–8.
pubmed: 25700303
Tai CC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, et al. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. Am J Clin Oncol. 2020;43(1):28–34.
pubmed: 31693507
Huang SC, Lin CC, Teng HW, Lin HH, Chang SC, Lan YT, Wang HS, Yang SH, Chen WS, Jiang JK. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer. Front Oncol. 2022;12:808808.
pubmed: 35372058
pmcid: 8968042
Chen YH, Su YC, Hsu CW, Hsieh MC, Wang YC, Lee MH, Lin CY, Chang YC, Wu CC. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: a nationwide database study. Eur J Surg Oncol. 2023;49(2):445–51.
pubmed: 36208981
Yoshino T, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, et al. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer. Cancer Sci. 2023;114(3):1026–36.
pubmed: 36369901
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021;32(9):1137–47.
pubmed: 34139272
Lee YC, Huang WT, Lee MY, Tsao CJ, Feng YH. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial. In Vivo. 2023;37(1):454–60.
pubmed: 36593061
pmcid: 9843751
Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5.
pubmed: 19114704
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253–9.
pubmed: 17317837
Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173–80.
pubmed: 18834263
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
pubmed: 17167137
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–34.
pubmed: 19188680
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, et al. BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–204.
pubmed: 26014294
Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L. Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol. 2017;135(1):99–105.
pubmed: 28667595
Hafkamp HC, Mooren JJ, Claessen SM, Klingenberg B, Voogd AC, Bot FJ, Klussmann JP, Hopman AH, Manni JJ, Kremer B, et al. P21 Cip1/WAF1 expression is strongly associated with HPV-positive tonsillar carcinoma and a favorable prognosis. Mod Pathol. 2009;22(5):686–98.
pubmed: 19305381
Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017;16(1):39.
pubmed: 28209170
pmcid: 5314465
Yin D, Lu X, Su J, He X, De W, Yang J, Li W, Han L, Zhang E. Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non-small cell lung cancer cell proliferation by epigenetically repressing p21 expression. Mol Cancer. 2018;17(1):92.
pubmed: 29793547
pmcid: 5968553
Kraus JA, Wenghoefer M, Glesmann N, Mohr S, Beck M, Schmidt MC, Schroder R, Berweiler U, Roggendorf W, Diete S, et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol. 2001;52(3):263–72.
pubmed: 11519857
Gervais JL, Seth P, Zhang H. Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem. 1998;273(30):19207–12.
pubmed: 9668108
Harvat BL, Wang A, Seth P, Jetten AM. Up-regulation of p27Kip1, p21WAF1/Cip1 and p16Ink4a is associated with, but not sufficient for, induction of squamous differentiation. J Cell Sci. 1998;111(Pt 9):1185–96.
pubmed: 9547295
McKay BC, Ljungman M, Rainbow AJ. Persistent DNA damage induced by ultraviolet light inhibits p21waf1 and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene. 1998;17(5):545–55.
pubmed: 9704920
Wu J, Liu L, Wu F, Qiu L, Luo M, Ke Q, Deng X, Luo Z. Clinical and prognostic implications of P21 (WAF1/CIP1) expression in patients with esophageal cancer: a systematic review and meta-analysis. Dis Markers. 2020;2020:6520259.
pubmed: 31998417
pmcid: 6970003
Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, von Deimling A. Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer. 1995;72(5):1230–3.
pubmed: 7577473
pmcid: 2033923
Rastinejad F, Blau HM. Genetic complementation reveals a novel regulatory role for 3’ untranslated regions in growth and differentiation. Cell. 1993;72(6):903–17.
pubmed: 8384533
Wang Z, Sturgis EM, Zhang F, Lei D, Liu Z, Xu L, Song X, Wei Q, Li G. Genetic variants of p27 and p21 as predictors for risk of second primary malignancy in patients with index squamous cell carcinoma of head and neck. Mol Cancer. 2012;11:17.
pubmed: 22449259
pmcid: 3331801
Su L, Liu G, Zhou W, Xu LL, Miller DP, Park S, Lynch TJ, Wain JC, Christiani DC. No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12(2):174–5.
pubmed: 12582031
Choi YY, Kang HK, Choi JE, Jang JS, Kim EJ, Cha SI, Lee WK, Kam S, Kim CH, Han SB, et al. Comprehensive assessment of P21 polymorphisms and lung cancer risk. J Hum Genet. 2008;53(1):87–95.
pubmed: 18046503